Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2022 | $20.00 → $11.00 | Overweight | Wells Fargo |
| 8/6/2021 | $17.00 → $15.00 | Buy | HC Wainwright & Co. |
Wells Fargo reiterated coverage of Celyad Oncology with a rating of Overweight and set a new price target of $11.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $15.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $17.00 from $18.00 previously
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a n
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration with the U.S. Securities and Exchange Commission (the "SEC") upon satisfaction of the requirements for deregistration. The Company will continue to be listed on Euronext Brussels. In connection w
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments. "Celyad Oncology is now fully committed to leveraging its expertise, know-how and intellectual p
15F-12B - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)